Herbosa CM, et al. - Researchers provided a comprehensive quality of life (QoL) assessment for early- and advanced-stage mycosis fungoides (MF)/Sézary syndrome (SS) and evaluated the correlation between traditional clinical severity measures and QoL measures. Outpatients at an academic medical center with either MF/SS (n = 115) or general dermatology concerns (n = 115) finished generic and dermatology-specific QoL instruments between July 2017 and April 2019. Using multivariable regression models adjusted for demographics and medical comorbidities, the mean scores of MF/SS patients were compared with that of controls. According to results, MF/SS patients scored significantly worse than controls on all QoL instruments used, with advanced-stage (IIB-IVB) disease having the worst impairment of QoL. Findings suggested that MF/SS have a significant impact on the QoL of patients in multiple domains including social, emotional and physical functioning. MF/SS had significantly worse skin-specific impairment than controls, with the most severe skin-specific burden reported by advanced-stage disease. Current clinical measures do not adequately address QoL outcomes, underlining the need to integrate formal disease-specific QoL evaluation into MF/SS patients' routine evaluation.